SelectScience
Join Free
CLINICAL24 2026
NewsClinical Diagnostics

Gradientech brings cefiderocol to rapid AST in just over 3 hours

Gradientech
20 Oct 2026
gradientech logo

Summary: Gradientech has launched QuickMIC® GN02, a new IVDR CE-marked rapid antibiotic susceptibility testing (AST) panel for challenging Gram-negative pathogens. Delivering susceptibility results in just 3 hours and 14 minutes, the panel includes cefiderocol and other important reserve antibiotics, expanding rapid AST options for multidrug-resistant Gram-negative bacteria.



Gradientech, a diagnostics company pioneering ultra-rapid antibiotic susceptibility testing (AST), today launches QuickMIC® GN02, an IVDR CE-marked AST panel that delivers susceptibility results for challenging Gram-negative pathogens in just 3 hours and 14 minutes.

Rapid AST is critical when every hour matters. The new panel adds cefiderocol and other important reserve antibiotics to the QuickMIC® portfolio, expanding testing options for multidrug-resistant Gram-negative bacteria and supporting faster, more informed treatment decisions.

Clinical and analytical performance data were strong across the evaluation, with 95.5% essential agreement, 96.0% categorical agreement, 98.9% reproducibility, and 99.6% of quality control results within range, comfortably exceeding regulatory performance requirements.

“QuickMIC GN02 represents a significant expansion of our rapid AST capabilities. Bringing cefiderocol into a rapid AST workflow is an important technical achievement, and we are proud to make this capability available to laboratories”, says Christer Malmberg, CSO at Gradientech. “It expands the clinical value of our QuickMIC platform and, importantly, gives laboratories more opportunities to deliver actionable results within the same rapid workflow.”

“For me, this is also about what we are building as a company”, says Sumi Thaker, CEO of Gradientech. “We want QuickMIC to become a trusted solution for laboratories facing increasingly complex resistance patterns. The team has made real progress, and I look forward to bringing this capability to more laboratories and clinicians.”

The QuickMIC® system is CE marked and commercially available in Europe. QuickMIC has been granted Breakthrough Device designation by the U.S. Food and Drug Administration and is available for Investigational Use Only in the U.S., but not 510(k) cleared.

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>

Related products

Request Quote for All Products

Links

GradientechCompany website

Tags

Clinical MicrobiologyMicrobiology is the study of microorganisms including protists, prokaryotes, fungi, and, often, viruses. Microorganisms are a useful research tool as genetic vectors and, in immunology, for antibiotic susceptibility testing, cellular biology and genetics. Microorganisms commonly grow readily in incubators with microbial culture media; this can contain chromogenic supplements to differentiate between cell lines. Estimate your culture’s density of microorganisms with colony counters, or screen and select colonies for desirable clones with automated colony pickers. Additionally, equipment is available to monitor environments for the presence of microbes and identify with microbial identification instruments. Find the best microbiology products in our peer-reviewed product directory: compare products, check customer reviews and receive pricing direct from manufacturers.Antimicrobial Resistance (AMR)Antibiotic ResistanceAntibiotic resistance poses a significant threat to public health driving innovation and change through antibiotic stewardship efforts. Ongoing research and diagnostic efforts focus on new treatments and detection methods. Explore antibiotic resistance research and diagnostic tools in our peer-reviewed product directory; compare products, check reviews, and get pricing directly from manufacturers.

Frequently asked questions

Show frequently asked questions

What is QuickMIC GN02?
QuickMIC® GN02 is an IVDR CE-marked antibiotic susceptibility testing (AST) panel from Gradientech. It is designed for testing challenging Gram-negative pathogens and delivers susceptibility results in 3 hours and 14 minutes.

How quickly does QuickMIC GN02 provide antibiotic susceptibility results?
QuickMIC GN02 provides antibiotic susceptibility testing results in 3 hours and 14 minutes, supporting laboratories seeking faster information to help inform antimicrobial treatment decisions.

Which bacteria is QuickMIC GN02 designed to test?
QuickMIC GN02 is designed for antibiotic susceptibility testing of challenging Gram-negative pathogens, including multidrug-resistant Gram-negative bacteria.

Does QuickMIC GN02 include cefiderocol susceptibility testing?
Yes. QuickMIC GN02 adds cefiderocol and other important reserve antibiotics to the QuickMIC portfolio, expanding rapid AST options for multidrug-resistant Gram-negative bacteria.

How can laboratories rapidly test multidrug-resistant Gram-negative bacteria?
Rapid antibiotic susceptibility testing systems such as Gradientech’s QuickMIC can shorten the time needed to generate susceptibility results. The QuickMIC GN02 panel delivers results for challenging Gram-negative pathogens in 3 hours and 14 minutes and includes cefiderocol and other reserve antibiotics.

Can laboratories perform rapid AST for cefiderocol?
Yes. Gradientech’s QuickMIC GN02 brings cefiderocol into the QuickMIC rapid AST workflow, enabling laboratories to assess susceptibility alongside other important antibiotics for challenging Gram-negative pathogens.

Related articles